Newsbenzinga
Genmab Stock Hits 52-Week High - Here's Why
· Published
Article summary
Genmab shares gain as petosemtamab cuts head and neck cancer death risk by 50%, backing William Blair's $8 billion peak sales projections.
An excerpt from the original article.
Comments —
Loading comments…